Download PDF
Exp Clin Endocrinol Diabetes 2012; 120(03): 164-168
DOI: 10.1055/s-0032-1301897
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Medullary Thyroid Carcinoma Surgical Cytoreduction Induces an Increase in Serum Calcitonin and Carcinoembryonic Antigen Doubling Times

P. Papapetrou
1   Division of Endocrinology, Alexandra Hospital, 11528 Athens, Greece
,
A. Polymeris
1   Division of Endocrinology, Alexandra Hospital, 11528 Athens, Greece
› Author Affiliations
Further Information

Publication History

received 28 November 2011
first decision 27 December 2011

accepted 18 January 2012

Publication Date:
10 February 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Serum calcitonin (Ct) and carcinoembryonic antigen (CEA) doubling times (DT) are considered to be strong prognostic markers in patients with medullary thyroid carcinoma (MTC). The Objective of this work is to study the effect of MTC debulking on Ct and CEA DTs. 4 patients with MTC are presented who after an initial neck operation had residual disease were followed-up with serial measurements of serum Ct and CEA for several years before and after a secondary incomplete removal of involved cervical lymph nodes.

The patients received no other treatment for MTC. Ct and CEA DTs were determined after fitting the Ct or CEA values to an exponential growth equation.

In patient A, Ct DT increased from 1.45 years (1.17–1.89, 95% CI) preoperatively, to 5.72 (3.22–25.77) postoperatively. In patient B, Ct DT was 1.63 years (1.36–2.02) preoperatively, and very long (serum Ct practically ceased increasing) postoperatively. In patient C, Ct DT was 4.03 years (2.22–21.58) before, and very long after the operation. In patient D, Ct DT from 1.16 years (0.82–1.99) before, increased to 4.21 years (3.04–6.86) after the operation. The changes in CEA DTs were similar to those of Ct DTs in 2 patients in whom the tumor was apparently producing the protein.

In conclusion, surgical MTC cytoreduction in 4 patients caused an increase in the Ct and CEA DTs, and the patients could be reclassified in new Ct DT-based strata with better prognosis than before the operation. We hypothesize that such tumor burden reduction may slow the growth of any residual MTC and we discuss mechanisms that could be responsible for this phenomenon.

Key words

medullary thyroid carcinoma cytoreduction - calcitonin doubling times - CEA doubling times
 

  • References

  • 1 Barbet J, Campion L, Kraeber-Bodéré F et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 6077-6084
    CrossrefPubMedGoogle Scholar
  • 2 Chigurupati S, Kulkarni T, Thomas S et al. Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 2005; 65: 8519-8529
    CrossrefPubMedGoogle Scholar
  • 3 Cohen R, Campos JM, Salaün C et al., and Groupe d’étude des tumeurs à calcitonine (GETC) . Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 919-922
    CrossrefPubMedGoogle Scholar
  • 4 Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004; 10: 942-949
    CrossrefPubMedGoogle Scholar
  • 5 Fleming JB, Lee JE, Bouvet M et al. Surgical strategy for the management of medullary thyroid carcinoma. Ann Surg 1999; 230: 697-707
    CrossrefPubMedGoogle Scholar
  • 6 Gawlik T, d’Amico A, Szpak-Ulczoc S et al. The prognostic value of tumor markers doubling times in medullary thyroid carcinoma-preliminary report. Thyroid Research 2010; 3: 10-15
    CrossrefPubMedGoogle Scholar
  • 7 Giraudet AL, Ghulzan AA, Aupérin A et al. Progression of medullary thyroid carcinoma : assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158: 239-246
    CrossrefPubMedGoogle Scholar
  • 8 Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association THYROID 2009; 19: 565-612
    PubMed
  • 9 Meijer JAA, le Cessie S, van den Hout WB et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-anlysis. Clin Endocrinol (Oxf) 2010; 72: 534-542
    CrossrefPubMedGoogle Scholar
  • 10 Miyauchi A, Onishi T, Morimoto S et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 1984; 199: 461-466
    CrossrefPubMedGoogle Scholar
  • 11 Müller S, Poehnert D, Müller JA et al. Regulatory T cells in peripheral blood, lymph node, and thyroid tissue in patients with medullary thyroid carcinoma. World J Surg 2010; 34: 1481-1487
    CrossrefPubMedGoogle Scholar
  • 12 Napoletano C, Bellati F, Landi R et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010; 14: 2748-2759
    CrossrefPubMedGoogle Scholar
  • 13 Pantazi H, Papapetrou PD. Calcitonin levels are similar in goitrous euthyroid patients with or without thyroid antibodies, as well as in hypothyroid patients. Eur J Endocrinol 1998; 138: 530-535
    CrossrefPubMedGoogle Scholar
  • 14 Schorge JO, McCann C, Del Carmen MG. Surgical debulking of ovarian cancer: what difference does it make?. Rev Obstet Gynecol 2010; 3: 111-117
    PubMedGoogle Scholar
  • 15 Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-4772
    PubMedGoogle Scholar
  • 16 Zhu W, Hai T, Cote GJ. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on RET proto-oncogene activity. J Clin Endocrinol Metab 2010; 95: 439-444
    CrossrefPubMedGoogle Scholar